Enanta Pharmaceuticals Inc (ENTA) : Mcclain Value Management scooped up 80,342 additional shares in Enanta Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 186,850 shares of Enanta Pharmaceuticals Inc which is valued at $4,372,290.Enanta Pharmaceuticals Inc makes up approximately 3.50% of Mcclain Value Management’s portfolio.
Other Hedge Funds, Including , Cable Hill Partners reduced its stake in ENTA by selling 187 shares or 90.78% in the most recent quarter. The Hedge Fund company now holds 19 shares of ENTA which is valued at $418.Strs Ohio boosted its stake in ENTA in the latest quarter, The investment management firm added 4,800 additional shares and now holds a total of 29,000 shares of Enanta Pharmaceuticals Inc which is valued at $630,170.Eqis Capital Management reduced its stake in ENTA by selling 5,510 shares or 10.69% in the most recent quarter. The Hedge Fund company now holds 46,015 shares of ENTA which is valued at $1,010,950. Enanta Pharmaceuticals Inc makes up approx 0.07% of Eqis Capital Management’s portfolio.Cutler Group Lp boosted its stake in ENTA in the latest quarter, The investment management firm added 3,520 additional shares and now holds a total of 4,300 shares of Enanta Pharmaceuticals Inc which is valued at $94,987. Enanta Pharmaceuticals Inc makes up approx 0.01% of Cutler Group Lp’s portfolio.
Enanta Pharmaceuticals Inc opened for trading at $23.09 and hit $23.27 on the upside on Wednesday, eventually ending the session at $23.2, with a gain of 0.22% or 0.05 points. The heightened volatility saw the trading volume jump to 2,15,074 shares. Company has a market cap of $442 M.
On the company’s financial health, Enanta Pharmaceuticals Inc reported $-0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.09. The company had revenue of $14.00 million for the quarter, compared to analysts expectations of $13.95 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 EPS.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.